IGF-1 LR3
Insulin-Like Growth Factor Variant
Dosage
1mg
Unit Size
1 Vial
// Add to Cart
1mg
$100.00
39 in stock
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic analog of naturally occurring IGF-1, modified at the N-terminus with an arginine substitution that prevents binding to IGF-binding proteins in circulation. This modification dramatically extends its half-life to 20–30 hours compared to just minutes for native IGF-1, making it a highly studied research compound for anabolic, metabolic, and cell growth investigations.
20–30h
Half-life
83 aa
Amino Acid Chain
LR3
Modified Variant
Key Benefits
Muscle Cell Proliferation
Promotes skeletal muscle satellite cell differentiation and proliferation, driving lean muscle tissue development.
Nitrogen Retention
Supports nitrogen retention in muscle tissue, a key marker for anabolic activity in research models.
Enhanced Nutrient Uptake
Enhances cellular nutrient uptake and amino acid transport into muscle tissue for growth and repair.
Fat Metabolism
Studied for its role in promoting lipolysis and shifting substrate utilization toward fat as a fuel source.
Cartilage & Bone Activity
May support chondrocyte and osteoblast activity, with research interest in joint and bone health applications.
Extended Bioavailability
The LR3 modification prevents IGFBP binding, giving IGF-1 LR3 significantly longer activity windows than native IGF-1.
How It Works
IGF-1 Receptor Binding
IGF-1 LR3 binds to the IGF-1 receptor (IGF1R) on muscle and other target cells, initiating downstream anabolic signaling.
PI3K/AKT Pathway Activation
Receptor activation triggers the PI3K/AKT signaling cascade, promoting cell survival, protein synthesis, and glucose uptake.
MAPK Pathway Stimulation
Simultaneously activates the MAPK/ERK pathway, driving cell division, proliferation, and differentiation in muscle and connective tissue.
IGFBP Resistance
The LR3 modification prevents binding to insulin-like growth factor binding proteins, allowing greater free peptide availability and prolonged receptor activity.
Common Protocol (Research Reference)
50–100 mcg
Dose per injection
1×/day
Frequency
4–6 wks
Typical cycle length
Research Use Notice
IGF-1 LR3 is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.